PCM
FBIO icon

Prelude Capital Management’s Fortress Biotech FBIO Stock Holding History

Prelude Capital Management’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Buy
+41,507
New +$107K 0.01% 1075
2018
Q1 		– Sell
-425
Closed -$25K – 1576
2017
Q4 		$25K Buy
+425
New +$25K ﹤0.01% 1088
2013
Q4 		– Sell
-85
Closed -$9K – 1703
2013
Q3 		$9K Buy
+85
New +$10.4K ﹤0.01% 1309

Other funds holding FBIO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Prelude Capital Management's FBIO Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Fortress Biotech (FBIO) in Q2 2026: 41,507 shares worth $127K. The stake represents 0.01% of the portfolio and ranks #1075 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in FBIO as recently as Q4 2017.

Prelude Capital Management first reported a position in FBIO in Q3 2013 and has held it in 3 quarters since. 55 funds tracked by Wall St. Rank hold FBIO as of Q2 2026.

  • Prelude Capital Management held 41,507 shares of Fortress Biotech worth $127K as of Q2 2026.
  • Fortress Biotech was a new Prelude Capital Management position in Q2 2026.
  • Fortress Biotech made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1075 holding.
  • Prelude Capital Management first reported a position in Fortress Biotech in Q3 2013 and has held it in 3 quarters since.
  • 55 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.